Adrenoleukodystrophy Drugs Global Market Report 2025
상품코드:1750892
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
부신백질이영양증 치료제 시장 규모는 앞으로 수년간 급성장할 것으로 전망됩니다. 2029년에는 10억 5,000만 달러로 성장하며, CAGR은 10.9%를 나타낼 전망입니다. 예측기간에 예측되는 성장은 희소질환 연구에 대한 투자 증가, 정밀의료 채용 확대, 개발도상지역에서의 헬스케어 지출 증가, 신생아 스크리닝 프로그램 강화, 희소 의약품 개발에 대한 규제 당국의 지원 등에 기인하고 있습니다. 이 기간의 주요 동향으로는 AI를 활용한 창약, 조기 진단을 위한 차세대 시퀀서, 나노기술을 활용한 약물전달, 줄기세포 유전자 치료의 혁신, 바이오테크놀러지 기업간의 제휴 등을 들 수 있습니다.
건강 관리 지출 증가는 부신백질이영양증 치료제 시장의 주요 촉진요인입니다. 헬스케어 지출은 의료 서비스, 헬스케어 제품 및 관련 서비스에 할당된 총 재원을 포함하여 증가하는 경향이 있습니다. 이것은 인구의 고령화와 만성 질환의 만연에 의한 점이 크고, 모두 장기적인 케어와 지속적인 관리가 필요합니다. 그 결과, 부신백질이영양증(ALD)을 포함한 희귀질환의 전문적 치료에 대한 요구가 증가하고, 연구 개발 및 환자 관리 비용이 증가하고 있습니다. 메디케어 메디케이드 서비스 센터(CMS)에 따르면 미국의 국민 의료비는 2023년 7.5% 증가해 GDP 성장률을 웃돌았고 2023년부터 2032년까지는 연률 5.6%를 나타낼 것으로 예측됩니다. 건강 관리 지출이 증가함에 따라 ALD 치료제와 같은 치료 수요도 증가하고 시장 성장이 촉진됩니다.
FDA 및 EMA와 같은 규제 당국의 승인은 ALD와 같은 희귀질환의 치료 옵션을 확대하는 데 매우 중요합니다. Therapeutics사가 있습니다. 이 회사는 2023년 5월, X연쇄성 부신백질이영양증(X-ALD) 및 뇌성 부신백질이영양증(cALD)의 성인 남성 환자를 대상으로 한 레리글리타존(MIN-102)의 제3상 임상시험을 개시하기 위한 FDA 승인을 취득했습니다. 알려진 이 임상시험은 이 약이 질병의 진행을 늦추거나 멈추는 능력을 평가하는 것으로, 치료의 선택사항이 한정되어 있는 환자에게 희망을 주는 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 부신백질이영양증 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 부신백질이영양증 치료제 시장 : 성장률 분석
세계의 부신백질이영양증 치료제 시장 실적 : 규모와 성장(2019-2024년)
세계의 부신백질이영양증 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 부신백질이영양증 치료제 전체 시장(TAM)
제6장 시장 세분화
세계의 부신백질이영양증 치료제 시장 : 약제 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
식이보충제
항산화제
코르티코스테로이드
효소 대체 요법
세계의 부신백질이영양증 치료제 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소아 뇌부신백질이영양증
애디슨병
부신수질신경병증(AMN)
세계의 부신백질이영양증 치료제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
주사제
정맥
세계의 부신백질이영양증 치료제 시장 : 환자 연령층별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소아 환자
성인 환자
노인 환자
세계의 부신백질이영양증 치료제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 부신백질이영양증 치료제 시장 : 식이보충제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
오메가3 지방산
비타민
아미노산
미네랄
세계의 부신백질이영양증 치료제 시장 : 항산화제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
비타민 E
코엔자임 Q10
알파-리포산
글루타치온
세계의 부신백질이영양증 치료제 시장 : 코르티코스테로이드 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
프레드니손
덱사메타손
하이드로코르티손
메틸프레드니솔론
세계의 부신백질이영양증 치료제 시장 : 효소 대체 요법 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
라로니다제
이두설파제
갈설파제
세베리파제 알파
제7장 지역별/국가별 분석
세계의 부신백질이영양증 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 부신백질이영양증 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
부신백질이영양증 치료제 시장 : 경쟁 구도
부신백질이영양증 치료제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Teva Pharmaceuticals USA Inc.
Dr. Reddy's Laboratories
Poxel SA
Neuraxpharm
Mallinckrodt Pharmaceuticals plc
Nutricia
Viking Therapeutics Inc.
MedDay Pharmaceuticals SAS
Voyager Therapeutics Inc.
Prevail Therapeutics
Ashvattha Therapeutics
Magenta Therapeutics Inc.
Minoryx Therapeutics SL
SwanBio Therapeutics Inc.
Autobahn Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
부신백질이영양증 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
부신백질이영양증 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
부신백질이영양증 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Adrenoleukodystrophy (ALD) drugs are used to manage symptoms and slow the progression of ALD, a rare genetic disorder that impacts the nervous system and adrenal glands. This condition is caused by mutations in the ABCD1 gene, leading to the buildup of very long-chain fatty acids (VLCFAs) in the brain, adrenal glands, and spinal cord.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary drug categories for treating ALD include dietary supplements, antioxidants, corticosteroids, and enzyme replacement therapy. Dietary supplements are oral products containing essential nutrients such as vitamins, minerals, amino acids, and fatty acids, which support overall health and may help manage conditions such as ALD. These treatments are used for a range of conditions, including childhood cerebral adrenoleukodystrophy (CCALD), Addison's disease, and adrenomyeloneuropathy (AMN), and can be administered via oral, injectable, or intravenous routes. They are suitable for different age groups, including pediatric, adult, and geriatric populations, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels.
The adrenoleukodystrophy drugs market research report is one of a series of new reports from The Business Research Company that provides adrenoleukodystrophy drugs market statistics, including adrenoleukodystrophy drugs industry global market size, regional shares, competitors with an adrenoleukodystrophy drugs market share, detailed adrenoleukodystrophy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the adrenoleukodystrophy drugs industry. This adrenoleukodystrophy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The adrenoleukodystrophy drug market size has grown rapidly in recent years. It will grow from$0.63 billion in 2024 to $0.70 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth observed during the historical period can be attributed to heightened awareness of rare diseases, a rise in orphan drug designations, government funding for rare disease research, the development of personalized medicine, and the expansion of healthcare infrastructure.
The adrenoleukodystrophy drugs market size is expected to see rapid growth in the next few years. It will grow to$1.05 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth projected for the forecast period can be attributed to increased investment in rare disease research, the growing adoption of precision medicine, rising healthcare expenditure in developing regions, enhanced newborn screening programs, and regulatory support for orphan drug development. Key trends during this period include AI-driven drug discovery, next-generation sequencing for early diagnosis, nanotechnology-based drug delivery, innovations in stem cell gene therapy, and collaborations between biotech companies.
The growth of healthcare expenditure is a key driver of the adrenoleukodystrophy (ALD) drugs market. Healthcare expenditure, which includes the total financial resources allocated to medical services, healthcare products, and related services, is on the rise. This is largely due to an aging population and the growing prevalence of chronic diseases, both of which demand long-term care and continuous management. As a result, there is an increased need for specialized treatments for rare diseases, including ALD, which in turn leads to higher costs for research, development, and patient care. According to the Centers for Medicare and Medicaid Services (CMS), U.S. national health expenditures grew 7.5% in 2023, outpacing GDP growth, and are projected to grow at an annual rate of 5.6% from 2023 to 2032. As healthcare expenditure increases, so does the demand for treatments such as ALD drugs, fostering market growth.
Regulatory approvals from agencies such as the FDA and EMA are crucial for expanding the range of treatment options available for rare diseases such as ALD. These approvals ensure that treatments meet the necessary safety and efficacy standards, enabling their market introduction. A notable example is Minoryx Therapeutics, a Spain-based biotechnology company, which in May 2023 received FDA approval to initiate a Phase 3 clinical trial for leriglitazone (MIN-102) in adult male patients with X-linked adrenoleukodystrophy (X-ALD) and cerebral adrenoleukodystrophy (cALD). This clinical trial, known as CALYX, will assess the drug's ability to slow or halt disease progression, providing hope to patients with limited treatment options. A successful trial could lead to commercialization, addressing an urgent medical need for patients suffering from these devastating conditions.
In November 2022, Minoryx Therapeutics entered into a strategic partnership with Neuraxpharm Group to secure exclusive commercialization rights for leriglitazone in Europe. Neuraxpharm, a Germany-based pharmaceutical company specializing in treatments for central nervous system (CNS) disorders, including rare diseases such as X-ALD, will leverage its expertise in the European market to accelerate the commercialization of leriglitazone. This collaboration aims to improve patient access to this promising treatment and support the continued growth of the ALD drug market.
Major players in the adrenoleukodystrophy drugs market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Teva Pharmaceuticals USA Inc., Dr. Reddy's Laboratories, Poxel S.A., Neuraxpharm, Mallinckrodt Pharmaceuticals plc, Nutricia, Viking Therapeutics Inc., MedDay Pharmaceuticals SAS, Voyager Therapeutics Inc., Prevail Therapeutics, Ashvattha Therapeutics, Magenta Therapeutics Inc., Minoryx Therapeutics S.L., SwanBio Therapeutics Inc., Autobahn Therapeutics Inc., bluebird bio Inc., SOM Biotech, and NeuroVia.
North America was the largest region in the adrenoleukodystrophy drugs market in 2024. The regions covered in adrenoleukodystrophy drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the adrenoleukodystrophy drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The adrenoleukodystrophy drugs market consists of sales of products including corticosteroids, Lorenzo's oil, hydrocortisone tablets, prednisone tablets, and adrenocortical hormone replacement therapy products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Adrenoleukodystrophy Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on adrenoleukodystrophy drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for adrenoleukodystrophy drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adrenoleukodystrophy drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Dietary Supplements; Antioxidants; Corticosteroids; Enzyme Replacement Therapy
2) By Indication: Childhood Cerebral Adrenoleukodystrophy; Addison's Disease; Adrenomyeloneuropathy (AMN)
3) By Route Of Administration: Oral; Injectable; Intravenous
4) By Patient Age Group: Pediatric Patients; Adult Patients; Geriatric Patients
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
3. Adrenoleukodystrophy Drugs Market Trends And Strategies
4. Adrenoleukodystrophy Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Adrenoleukodystrophy Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Adrenoleukodystrophy Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Adrenoleukodystrophy Drugs Market Growth Rate Analysis
5.4. Global Adrenoleukodystrophy Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Adrenoleukodystrophy Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Adrenoleukodystrophy Drugs Total Addressable Market (TAM)
6. Adrenoleukodystrophy Drugs Market Segmentation
6.1. Global Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dietary Supplements
Antioxidants
Corticosteroids
Enzyme Replacement Therapy
6.2. Global Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Childhood Cerebral Adrenoleukodystrophy
Addison's Disease
Adrenomyeloneuropathy (AMN)
6.3. Global Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Intravenous
6.4. Global Adrenoleukodystrophy Drugs Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric Patients
Adult Patients
Geriatric Patients
6.5. Global Adrenoleukodystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.6. Global Adrenoleukodystrophy Drugs Market, Sub-Segmentation Of Dietary Supplements, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Omega-3 Fatty Acids
Vitamins
Amino Acids
Minerals
6.7. Global Adrenoleukodystrophy Drugs Market, Sub-Segmentation Of Antioxidants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vitamin E
Coenzyme Q10
Alpha-Lipoic Acid
Glutathione
6.8. Global Adrenoleukodystrophy Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prednisone
Dexamethasone
Hydrocortisone
Methylprednisolone
6.9. Global Adrenoleukodystrophy Drugs Market, Sub-Segmentation Of Enzyme Replacement Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Laronidase
Idursulfase
Galsulfase
Sebelipase Alfa
7. Adrenoleukodystrophy Drugs Market Regional And Country Analysis
7.1. Global Adrenoleukodystrophy Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Adrenoleukodystrophy Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Adrenoleukodystrophy Drugs Market
9.1. China Adrenoleukodystrophy Drugs Market Overview
9.2. China Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Adrenoleukodystrophy Drugs Market
10.1. India Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Adrenoleukodystrophy Drugs Market
11.1. Japan Adrenoleukodystrophy Drugs Market Overview
11.2. Japan Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Adrenoleukodystrophy Drugs Market
12.1. Australia Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Adrenoleukodystrophy Drugs Market
13.1. Indonesia Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Adrenoleukodystrophy Drugs Market
14.1. South Korea Adrenoleukodystrophy Drugs Market Overview
14.2. South Korea Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Adrenoleukodystrophy Drugs Market
15.1. Western Europe Adrenoleukodystrophy Drugs Market Overview
15.2. Western Europe Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Adrenoleukodystrophy Drugs Market
16.1. UK Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Adrenoleukodystrophy Drugs Market
17.1. Germany Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Adrenoleukodystrophy Drugs Market
18.1. France Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Adrenoleukodystrophy Drugs Market
19.1. Italy Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Adrenoleukodystrophy Drugs Market
20.1. Spain Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Adrenoleukodystrophy Drugs Market
21.1. Eastern Europe Adrenoleukodystrophy Drugs Market Overview
21.2. Eastern Europe Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Adrenoleukodystrophy Drugs Market
22.1. Russia Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Adrenoleukodystrophy Drugs Market
23.1. North America Adrenoleukodystrophy Drugs Market Overview
23.2. North America Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Adrenoleukodystrophy Drugs Market
24.1. USA Adrenoleukodystrophy Drugs Market Overview
24.2. USA Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Adrenoleukodystrophy Drugs Market
26.1. South America Adrenoleukodystrophy Drugs Market Overview
26.2. South America Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Adrenoleukodystrophy Drugs Market
27.1. Brazil Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Adrenoleukodystrophy Drugs Market
28.1. Middle East Adrenoleukodystrophy Drugs Market Overview
28.2. Middle East Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Adrenoleukodystrophy Drugs Market
29.1. Africa Adrenoleukodystrophy Drugs Market Overview
29.2. Africa Adrenoleukodystrophy Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Adrenoleukodystrophy Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Adrenoleukodystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Adrenoleukodystrophy Drugs Market Competitive Landscape And Company Profiles
